146 related articles for article (PubMed ID: 36612081)
1. Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models.
Medina-Gutiérrez E; García-León A; Gallardo A; Álamo P; Alba-Castellón L; Unzueta U; Villaverde A; Vázquez E; Casanova I; Mangues R
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612081
[TBL] [Abstract][Full Text] [Related]
2. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
[TBL] [Abstract][Full Text] [Related]
3. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
4. A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model.
Rioja-Blanco E; Gallardo A; Arroyo-Solera I; Álamo P; Casanova I; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456719
[TBL] [Abstract][Full Text] [Related]
5. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.
Núñez Y; Garcia-León A; Falgàs A; Serna N; Sánchez-García L; Garrido A; Sierra J; Gallardo A; Unzueta U; Vázquez E; Villaverde A; Mangues R; Casanova I
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986589
[TBL] [Abstract][Full Text] [Related]
6. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract][Full Text] [Related]
8. Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease.
Medina-Gutiérrez E; Céspedes MV; Gallardo A; Rioja-Blanco E; Pavón MÀ; Asensio-Puig L; Farré L; Alba-Castellón L; Unzueta U; Villaverde A; Vázquez E; Casanova I; Mangues R
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884987
[TBL] [Abstract][Full Text] [Related]
9. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases.
Sala R; Rioja-Blanco E; Serna N; Sánchez-García L; Álamo P; Alba-Castellón L; Casanova I; López-Pousa A; Unzueta U; Céspedes MV; Vázquez E; Villaverde A; Mangues R
Drug Deliv; 2022 Dec; 29(1):1384-1397. PubMed ID: 35532120
[TBL] [Abstract][Full Text] [Related]
10. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
11. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
[TBL] [Abstract][Full Text] [Related]
12. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Falgàs A; Pallarès V; Unzueta U; Céspedes MV; Arroyo-Solera I; Moreno MJ; Sierra J; Gallardo A; Mangues MA; Vázquez E; Villaverde A; Mangues R; Casanova I
Haematologica; 2020 Mar; 105(3):741-753. PubMed ID: 31248974
[TBL] [Abstract][Full Text] [Related]
13. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4
Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; Mangues R; Alba-Castellón L; León X
Acta Pharm Sin B; 2022 May; 12(5):2578-2591. PubMed ID: 35646535
[TBL] [Abstract][Full Text] [Related]
14. Selective CXCR4
Díaz R; Pallarès V; Cano-Garrido O; Serna N; Sánchez-García L; Falgàs A; Pesarrodona M; Unzueta U; Sánchez-Chardi A; Sánchez JM; Casanova I; Vázquez E; Mangues R; Villaverde A
Small; 2018 Jun; 14(26):e1800665. PubMed ID: 29845742
[TBL] [Abstract][Full Text] [Related]
15. Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
Céspedes MV; Unzueta U; Aviñó A; Gallardo A; Álamo P; Sala R; Sánchez-Chardi A; Casanova I; Mangues MA; Lopez-Pousa A; Eritja R; Villaverde A; Vázquez E; Mangues R
EMBO Mol Med; 2018 Oct; 10(10):. PubMed ID: 30190334
[TBL] [Abstract][Full Text] [Related]
16. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
17. Fluorescent Dye Labeling Changes the Biodistribution of Tumor-Targeted Nanoparticles.
Álamo P; Pallarès V; Céspedes MV; Falgàs A; Sanchez JM; Serna N; Sánchez-García L; Voltà-Duràn E; Morris GA; Sánchez-Chardi A; Casanova I; Mangues R; Vazquez E; Villaverde A; Unzueta U
Pharmaceutics; 2020 Oct; 12(11):. PubMed ID: 33105866
[TBL] [Abstract][Full Text] [Related]
18. A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy.
Zhao Z; Huang Y; Wang J; Lin H; Cao F; Li S; Li Y; Li Z; Liu X
Biomater Sci; 2023 Mar; 11(6):2200-2210. PubMed ID: 36745434
[TBL] [Abstract][Full Text] [Related]
19. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
Pallarès V; Unzueta U; Falgàs A; Aviñó A; Núñez Y; García-León A; Sánchez-García L; Serna N; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Cedó L; Eritja R; Villaverde A; Vázquez E; Casanova I; Mangues R
Biomaterials; 2022 Jan; 280():121258. PubMed ID: 34847435
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
